The 502B pathway is straightforward. It is possible at the company is in talks with the FDA about evidence in the data needed for approval at this time with no more studies. With approval and superior efficacy the company may be able to go directly to market finding only a partner for sales and distribution. A similar path way may be in the works for BROM. As well as the forSP. That’s three lotto tickets bought and paid for just waiting for the man to pull the ping-pong balls out of the box.